New Insulins,Biosimilars,and Insulin Therapy

Ziegler AG , Danne T , Daniel C , Bonifacio E . 100 Years of insulin: lifesaver, immune target, and potential remedy for prevention. Med (N Y). 2021; 2: 1120–1137.

Mathieu C , Martens PJ , Vangoitsenhoven R . One hundred years of insulin therapy. Nat Rev Endocrinol, 2021; 17: 715–725.

Keeping the 100-year-old promise: making insulin access universal [article online], November 12, 2021. Available at www.who.int/publications/i/item/9789240039100.

Pettus J , Santos Cavaiola T , Tamborlane WV , Edelman S . The past, present, and future of basal insulins. Diabetes Metab Res Rev, 2016; 32: 478–496.

Sarkar S , Heyward J , Alexander GC , Kalyani RR . Trends in insulin types and devices used by adults with type 2 diabetes in the United States, 2016 to 2020. JAMA Netw Open 2021;4: e2128782.

van den Boom L , Kostev K . Patterns of insulin therapy and insulin daily doses in children and adolescents with type 1 diabetes in Germany. Diabetes Obes Metab, 2022; 24: 296–301.

Pedersen-Bjergaard U , Agesen RM , Brøsen JMB , et al. Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia: the HypoDeg randomized, controlled, open-label, crossover trial. Diabetes Obes Metab, 2022; 24: 257–267.

Brøsen JMB , Agesen RM , Alibegovic AC , et al. Continuous glucose monitoring-recorded hypoglycemia with insulin degludec or insulin glargine U100 in people with type 1 diabetes prone to nocturnal severe hypoglycemia. Diabetes Technol Ther, 2022; 24: 643–654.

Goldenberg RM , Aroda VR , Billings LK , et al. Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia. Diabetes Obes Metab, 2021; 23: 2572–2581.

Ringholm L , Callesen Do N , Damm P , Mathiesen ER . Pregnancy outcomes in women with type 1 diabetes using insulin degludec. Acta Diabetol, 2022; 59: 721–727.

Research Study Comparing Insulin Degludec to Insulin Detemir , Together with Insulin Aspart , in Pregnant Women with Type 1 Diabetes (EXPECT) [article online], accessed August 21 2022 . Available at https://clinicaltrials.gov/ct2/show/NCT03377699.

Nishimura E , Pridal L , Glendorf T , et al. Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing. BMJ Open Diabetes Res Care, 2021; 9: e002301.

Moyers JS , Hansen RJ , Day JW , et al. Preclinical characterization of LY3209590, a novel weekly basal insulin Fc-fusion protein. J Pharmacol Exp Ther, 2022; 382: 346–355.

White J , Wagner A , Patel H . The impact of biosimilar insulins on the diabetes landscape. J Manag Care Spec Pharm, 2022; 28: 91–98.

Beran D , Ewen M , Laing R . Constraints and challenges in access to insulin: a global perspective. Lancet Diabetes Endocrinol, 2016; 4: 275–285.

Beran D , Gale EAM , Yudkin JS . The insulin market reaches 100. Diabetologia, 2022; 65: 931–935.

Bloomgarden ZT . Biosimilar insulin concepts. J Diabetes. 2022; 14: 231–235.

Civica to Manufacture and Distribute Affordable Insulin [article online], March 3, 2022. Available at https://civicarx.org/wp-content/uploads/2022/03/Civica-Affordable-Insulin-Press-Release-03.03.22.pdf.

Kuehn BM . First interchangeable biosimilar insulin drug is approved. JAMA. 2021; 326: 801.

Matli MC , Wilson AB , Rappsilber LM , Sheffield FP , Farlow ML , Johnson JL . The First interchangeable biosimilar insulin: insulin glargine-yfgn. J Diabetes Sci Technol Dec 31; 19322968211067511. doi: 10.1177/19322968211067511. Online ahead of print.

Pham TT , Chen X , Barron J , Hart R , Abarca J , DeVries A . Effectiveness, safety, and treatment adherence of biosimilar follow-on insulin in diabetes management. Diabetes Obes Metab, 2022; 24: 1989–1997.

Fisher A , Kim JD , Dormuth C . The impact of mandatory nonmedical switching from originator to biosimilar insulin glargine. Clin Ther, 2022; 44: 957–970.

Hayes KN , Mor V , Zullo AR . Electronic health records to rapidly assess biosimilar uptake: an example using insulin glargine in a large U.S. nursing home cohort. Front Pharmacol, 2022; 13: 855598.

Godman B , Haque M , Leong T , et al. The current situation regarding long-acting insulin analogues including biosimilars among African, Asian, European, and South American countries; findings and implications for the future. Front Public Health, 2021; 9: 671961.

Godman B , Wladysiuk M , McTaggart S , et al. Utilisation trend of long-acting insulin analogues including biosimilars across Europe: findings and implications. Biomed Res Int, 2021; 2021: 9996193.

Godman B , Haque M , Kumar S , et al. Current utilization patterns for long-acting insulin analogues including biosimilars among selected Asian countries and the implications for the future. Curr Med Res Opin, 2021; 3: 1529–1545.

Wang H , Zhou Y , Zhai X , et al. Evaluating glycemic control during Basalin or Lantus administration in adults with controlled type 2 diabetes mellitus using continuous glucose monitoring. Front Endocrinol (Lausanne). 2021; 12: 754820.

Yang LJ , Wu TW , Tang CH , Peng TR . Efficacy and immunogenicity of insulin biosimilar compared to their reference products: a systematic review and meta-analysis. BMC Endocr Disord, 2022; 22: 35.

Saunders H , Pham B , Loong D , et al. The cost-effectiveness of intermediate-acting, long-acting, ultralong-acting, and biosimilar insulins for type 1 diabetes mellitus: a systematic review. Value Health, 2022; 25: 1235–1252.

Hompesch M , Hawryluk A , Hernandez M , Uchil B , Wilmington A , Peterson L . Pharmacokinetic and pharmacodynamic bioequivalence between regular human insulin (rDNA origin) in 0.9% sodium chloride ready-to-use infusion 1 U/mL and 100 U/mL concentrate diluted to 1 U/mL in healthy males. Diabetes Obes Metab, 2021; 23: 2679–2686.

Vishwakarma G , Nupur N , Rathore AS . Assessing the structural and functional similarity of insulin glargine biosimilars. J Diabetes Sci Technol 2021 December 01; 19322968211058482. doi: 10.1177/19322968211058482. Online ahead of print.

Wang W , Song X , Lou Y , Du L , Zhu D , Zhou Z . Immunogenicity of LY2963016 insulin glargine and Lantus(R) insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus. Diabetes Obes Metab, 2022; 24: 1094–1104.

Yan X , Jiang S , Lou Y , Zhou Z . Comparable efficacy and safety between LY2963016 insulin glargine and insulin glargine (Lantus(R)) in Chinese patients with type 1 diabetes: a phase III, randomized, controlled trial. Diabetes Obes Metab, 2021; 23: 2226–2233.

Yan X , Feng C , Lou Y , Zhou Z . Efficacy and safety of LY2963016 insulin glargine in Chinese patients with type 1 diabetes previously treated with insulin glargine (Lantus((R))): a post hoc analysis of a randomized, open-label, phase 3 trial. Diabetes Ther, 2022; 13: 1161–1174.

Kapitza C , Nosek L , Schmider W , Teichert L , Mukherjee B , Nowotny I . A single-dose euglycaemic clamp study in two cohorts to compare the exposure of SAR341402 (insulin aspart) mix 70/30 with US- and European-approved versions of insulin aspart mix 70/30 and SAR341402 rapid-acting solution in subjects with type 1 diabetes. Diabetes Obes Metab, 2021; 23: 674–681.

Aravind SR , Singh KP , Aquitania G , et al. Biosimilar insulin aspart premix SAR341402 mix 70/30 versus originator insulin aspart mix 70/30 (NovoMix 30) in people with diabetes: a 26-week, randomized, open-label trial (GEMELLI M). Diabetes Ther, 2022; 13: 1053–1071.

Aravind SR , Singh KP , Mogylnytska L , et al. Efficacy, safety, and immunogenicity of biosimilar insulin aspart premix SAR341402 mix 70/30 compared with originator insulin aspart mix 70/30 in adults with diabetes (GEMELLI M): a subgroup analysis by prior type of premix insulin. Diabetes Ther, 2022; 13: 1299–1310.

Shiramoto M , Yoshihara T , Schmider W , et al. Pharmacokinetic and pharmacodynamic similarity between SAR341402 insulin aspart and Japan-approved NovoRapid in healthy Japanese subjects. Sci Rep, 2021; 11: 22931.

Shiramoto M , Yoshihara T , Schmider W , et al. Similar pharmacokinetics and pharmacodynamics of biosimilar SAR342434 insulin lispro and Japan-approved humalog insulin lispro in healthy Japanese subjects. Clin Pharmacol Drug Dev, 2022; 11: 754–760.

Hovelmann U , Raiter Y , Chullikana A , et al. Pharmacokinetic and pharmacodynamic bioequivalence of biosimilar MYL-1601D with US and European insulin aspart in healthy volunteers: a randomized, double-blind, crossover, euglycaemic glucose clamp study. Diabetes Obes Metab, 2021; 23: 2670–2678.

Plum-Morschel L , Singh G , Murugesan SMN , et al. Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin-R with the US-licensed Humulin(R) R formulation in healthy subjects: results from the RHINE-1 (Recombinant Human INsulin Equivalence-1) study. Diabetes Obes Metab, 2022; 24: 713–721.

Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues, accessed June 24, 2022 . Available at https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-non-clinical-clinical-development-similar-biological-medicinal-products-containing_en-0.pdf.

Plum-Morschel L , Klein O , Singh G , et al. Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar insulin 70/30 with US-licensed HUMULIN(R) 70/30 formulation in healthy subjects: results from the RHINE-3 (Recombinant Human INsulin Equivalence-3) study. Diabetes Obes Metab, 2022; 24: 1819–1828.

Drai RV , Karonova TL , Mayorov AY , et al. Clinical pharmacology of insulin aspart biosimilar GP40071: pharmacokinetic/pharmacodynamic comparability in hyperinsulinemic euglycemic clamp procedure. Clin Pharmacol Drug Dev, 2022; 11: 922–929.

Vencio S , Caiado-Vencio R , Caixeta LF , et al. A randomized pharmacokinetic and pharmacodynamic trial of two regular human insulins demonstrates bioequivalence in type 1 diabetes and availability of biosimilar insulin may improve access to this medication. Diabetes Obes Metab, 2022; 24: 1544–1552.

Bramlage P , Tittel SR , Müther S , et al. A comparison of the rapid-acting insulin analogue glulisine with lispro and aspart for the pump treatment of patients with type 1 diabetes. Acta Diabetol. 2022 Aug 7. doi: 10.1007/s00592-022-01939-3. Online ahead of print.

Billion L , Charleer S , Verbraeken L , et al. Glucose control using fast-acting insulin aspart in a real-world setting: a 1-year, two-center study in people with type 1 diabetes using continuous glucose monitoring. Diabetes Obes Metab, 2021; 23: 2716–2727.

Lane W , Faurby M , Husemoen LLN , Markovich DL , Rathor N , De Block C . Glycaemic control in people with diabetes starting treatment with fast-acting insulin aspart: a US database study. Diabetes Ther, 2021; 12: 3067–3077.

Bode B , Carlson A , Liu R , et al. Ultrarapid lispro demonstrates similar time in target range to lispro with a hybrid closed-loop system. Diabetes Technol Ther, 2021; 23: 828–836.

Morrison D , Zaharieva DP , Lee MH , et al. Comparable glucose control with fast-acting insulin aspart versus insulin aspart using a second-generation hybrid closed-loop system during exercise. Diabetes Technol Ther, 2022; 24: 93–101.

Deberles E , Morello R , Hardouin J , et al. The switch from rapid-acting to concentrated regular insulin improves glucose control in type 2 diabetes patients on pump therapy: a cohort survey. Diabetes Metab, 2022; 48: 101300.

Gorst-Rasmussen A , Sturis J , Ekelund M . Continuous glucose monitoring sensor glucose levels and insulin pump infusion set wear-time during treatment with fast-acting insulin aspart: a post hoc analysis of Onset 5. Diabetes Technol Ther, 2022; 24: 10–17.

Khadria A , Paavola CD , Maslov K , et al. Photoacoustic imaging reveals mechanisms of rapid-acting insulin formulations dynamics at the injection site. Mol Metab, 2022; 62: 101522.

Grant M , Heise T , Baughman R . Comparison of pharmacokinetics and pharmacodynamics of inhaled technosphere insulin and subcutaneous insulin lispro in the treatment of type 1 diabetes mellitus. Clin Pharmacokinet, 2022; 61: 413–422.

Kaiserman KB , Christiansen M , Bhavsar S , et al. Reduction in postprandial peak glucose with increased technosphere insulin dosage. J Diabetes Sci Technol 2022 Jul 14; 19322968221110622. doi: 10.1177/19322968221110622. Online ahead of print.

Weinstock RS , Bode BW , Garg SK , et al. Reduced hypoglycaemia using liver-targeted insulin in individuals with type 1 diabetes. Diabetes Obes Metab, 2022; 24: 1762–1769.

van Bon AC , Bode BW , Sert-Langeron C , DeVries JH , Charpentier G . Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial. Diabetes Technol Ther, 2011; 13: 607–614.

Kordonouri O , Biester T , Weidemann J , et al. Lipoatrophy in children, adolescents and adults with insulin pump treatment: Is there a beneficial effect of insulin glulisine?. Pediatr Diabetes, 2020; 21: 1285–1291.